Wir sind mit live! Mehr erfahren

CG Oncology

CGON

Börsenwert 5,31 Mrd. $

59,85 USD

-2,01

3,25 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-3,25 %

5 Tage

-5,64 %

1 Monat

-19,25 %

3 Monate

-13,88 %

6 Monate

-9,78 %

Seit Jahresbeginn

43,22 %

1 Jahr

43,01 %

5 Jahre

61,02 %

10 Jahre

61,02 %

Profil: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Mitarbeiter: 142

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 16,7 %

Neutral 75 %

Negativ 8,3 %

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms.

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Schaeffers Research

3 Stocks Call Traders Are Targeting Today

YPF, CGON, and IE are seeing unusually heavy call volume.

3 Stocks Call Traders Are Targeting Today

Schaeffers Research

15 Stocks to Watch With Short Squeeze Potential

Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.

15 Stocks to Watch With Short Squeeze Potential

CG Oncology to Present at Upcoming Investor Conferences in September

DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

CG Oncology to Present at Upcoming Investor Conferences in September

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

CG Oncology: Circling Back After Huge Rally

CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.

CG Oncology: Circling Back After Huge Rally

Zacks Investment Research

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt